Skip to main content
. 2010 Feb 24;2:14. doi: 10.3410/M2-14

Table 3. General features of multiple endocrine neoplasia syndrome type 1 (MEN1) predictive testing.

 •Diagnostic testing is appropriate in symptomatic individuals of any age.
 •Confirming a diagnosis may alter medical management for the individual.
 •It is medically indicated since early diagnosis allows interventions that reduce morbidity or mortality.
 •Even in the absence of medical indications, predictive testing can influence life planning decisions.
 •Molecular genetic testing of an affected family member may be required to determine the disease-causing mutation(s) present in the family.
 •Genetic testing should be offered to at-risk members of a family in which a germline MEN1 mutation has been identified in an affected relative. Identifying carriers allows reproductive choices.
 •A DNA test in MEN1 may be offered to children within the first decade because tumors such as insulinoma and pituitary adenomas have developed in some children by the age of 5 years.
 •Genetic counseling and education should accompany carrier testing because of the potential for personal and social concerns.
 •Many laboratories will not proceed with predictive testing without proof of informed consent and genetic counseling.
 •Identification of the specific gene mutation in an affected relative or establishment of linkage within the family should precede predictive testing.
 •Because predictive testing can have psychological ramifications, careful patient assessment, counseling, and follow-up are important.
 •Predictive testing of asymptomatic children at risk for an adult-onset or later-onset disorder is strongly discouraged when no medical intervention is available (American Society of Human Genetics/American College of Medical Genetics Policy Statement - 1995) [38].
 •If molecular genetic testing is not possible or is not informative, individuals at 50% risk (first-degree relatives of an individual with MEN1 syndrome) should undergo routine biochemical-clinical evaluation.
 •Currently, a DNA test identifying an individual as a MEN1 mutant gene carrier does not usually lead to immediate medical or surgical treatment, but it suggests precocious and frequent clinical screening.